In Silico Designed Novel Multi Epitope Vaccine Construct Towards Bundibugyo Ebolavirus

The aim of this research is to develop a protein-based vaccine for immunization against the Ebola virus disease (EVD) using immunological information and knowledge of structural biology. According to WHO reports the fatality rate of the EVD is around 67% in the year 2019. Particularly, the Bundibugyo Ebolaviruses has the least pathogenic fatality rate approximately around 37%. Moreover, in past outbreaks, the fatality rate is different from 25 to 95% due to a shortage of powerful medication and vaccines. In this present work, immunological information tools and databases to retrieve the highest antigenicity of B-cell and T-cell epitopes from Ebola virus (EBOV) glycoprotein. Vaccine was constructed using 5CD8+, 8CD4+, and 6B-cell epitope with suitable linkers. Mycobacterium tuberculosis lipoprotein has been introduced into the vaccine as an adjuvant to strengthen the vaccine's efficacy. Physicochemical properties of the developed vaccine were assessed, which incorporates solubility, stability, and so forth. The interactions between the vaccine and Toll-like receptors 3, 4, and 7, have been studied. The constructed vaccine demonstrates enhanced cellular immunity and also assesses the clearance of antigen from the body at various exposures.